Literature DB >> 16732022

Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers.

Claudia Langenberg1, Jaclyn Bergstrom, Christa Scheidt-Nave, Johannes Pfeilschifter, Elizabeth Barrett-Connor.   

Abstract

OBJECTIVE: Levels of adiposity-signaling hormones and inflammatory markers are less favorable in individuals with the metabolic syndrome; their role in the association between the metabolic syndrome and cardiovascular mortality remains unclear. RESEARCH DESIGN AND METHODS: We conducted a prospective study of 977 men and 1,141 women aged 40-94 years in 1984-1987, followed for mortality for a maximum of 20 years. Adiponectin, leptin, ghrelin, interleukin-6 (IL-6), C-reactive protein (CRP), and Adult Treatment Panel III-defined metabolic syndrome components were measured in fasting blood samples obtained in 1984-1987. Cox-proportional hazards models were used in survival analyses.
RESULTS: The age- and sex-adjusted hazard ratio (HR) (95% CI) for coronary heart disease (CHD) mortality associated with the metabolic syndrome was 1.65 (1.25-2.18) (P < 0.001); this association did not differ significantly by sex, age, or diabetic status (P > 0.2 for each interaction). The association between the metabolic syndrome and CHD mortality was not materially changed after adjustment for adiponectin, leptin, and ghrelin; it was attenuated by 25% after adjustment for IL-6 and 35% after adjustment for CRP. CHD mortality increased linearly with greater levels of IL-6 and CRP (P(trend) < 0.001 for each); the age- and sex-adjusted HRs comparing highest versus lowest quarter were 3.0 (1.87-4.89) for IL-6 and 2.1 (1.41-3.21) for CRP. IL-6, but not CRP, remained a significant predictor of CHD mortality in models including both inflammatory markers and the metabolic syndrome.
CONCLUSIONS: Adiposity-signaling hormones and inflammatory markers explain little to some of the association between the metabolic syndrome and CHD mortality. IL-6 levels predict CHD mortality independently of CRP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732022     DOI: 10.2337/dc05-2385

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  29 in total

1.  Adipose tissue as regulator of vascular tone.

Authors:  Charlotte Boydens; Nele Maenhaut; Bart Pauwels; Kelly Decaluwé; Johan Van de Voorde
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

2.  Increased Rho kinase activity in a Taiwanese population with metabolic syndrome.

Authors:  Ping-Yen Liu; Jyh-Hong Chen; Li-Jen Lin; James K Liao
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

Review 3.  Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease.

Authors:  C D A Stehouwer; R M A Henry; I Ferreira
Journal:  Diabetologia       Date:  2008-02-01       Impact factor: 10.122

4.  The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial.

Authors:  Shabnam Salekzamani; Abolhassan Shakeri Bavil; Hossein Mehralizadeh; Mohammad Asghari Jafarabadi; Aymaral Ghezel; Bahram Pourghassem Gargari
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

5.  The effect of prior walking on coronary heart disease risk markers in South Asian and European men.

Authors:  Saravana Pillai Arjunan; Kevin Deighton; Nicolette C Bishop; James King; Alvaro Reischak-Oliveira; Alice Rogan; Matthew Sedgwick; Alice E Thackray; David Webb; David J Stensel
Journal:  Eur J Appl Physiol       Date:  2015-10-05       Impact factor: 3.078

6.  Early inflammatory and metabolic changes in association with AGTR1 polymorphisms in prehypertensive subjects.

Authors:  Maple M Fung; Fangwen Rao; Sameer Poddar; Manjula Mahata; Srikrishna Khandrika; Sushil K Mahata; Daniel T O'Connor
Journal:  Am J Hypertens       Date:  2010-09-23       Impact factor: 2.689

7.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

8.  Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.

Authors:  Cecilia P Chung; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; Ingrid Avalos; Tuulikki Sokka; Paolo Raggi; Theodore Pincus; C Michael Stein
Journal:  Arthritis Rheum       Date:  2008-07

9.  Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample.

Authors:  Erik Ingelsson; Martin G Larson; Xiaoyan Yin; Thomas J Wang; James B Meigs; Izabella Lipinska; Emelia J Benjamin; John F Keaney; Ramachandran S Vasan
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

10.  Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside.

Authors:  Ana Villegas; Fernando A Gonzalez; Leopoldo Llorente; Santiago Redondo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.